Resetting the Evidence Bar for New Anticancer Drug Approvals - Takeaways - MDSpire

Resetting the Evidence Bar for New Anticancer Drug Approvals

  • By

  • Stacie B. Dusetzina

  • Shelley A. Jazowski

  • June 9, 2026

  • 0 min

Share

  • 1

    Many anticancer therapies are approved through expedited pathways, leading to information gaps for patients and families at the time of approval.

  • 2

    Patients often prioritize understanding treatment duration and quality of life, but accelerated approvals typically provide limited information on these outcomes.

  • 3

    Research indicates that most anticancer therapies do not show benefits in overall survival or quality of life within five years of accelerated approval.

  • 4

    Patients view the trade-off between rapid drug approval and clinical uncertainty as acceptable only when no alternative therapies exist or benefits are transformative.

  • 5

    Only 60% of drugs granted accelerated approval from 2013 to 2022 included patient-reported outcome measures, highlighting a need for better quality of life assessments.

Original Source(s)

Resetting the Evidence Bar for New Anticancer Drug Approvals

  • by Stacie B. Dusetzina, Shelley A. Jazowski

  • June 9, 2026

Related Content

A prediction model and risk stratification tool for survival by chemotherapy in invasive micropapillary carcinoma of the breast: a population-based study with external validation

Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial